Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Sharon A. McCarthy"'
Autor:
Sharon A. McCarthy, Matthew Chinman, Shari S. Rogal, Gloria Klima, Leslie R. M. Hausmann, Maria K. Mor, Mala Shah, Jennifer A. Hale, Hongwei Zhang, Adam J. Gordon, Walid F. Gellad
Publikováno v:
Implementation Research and Practice, Vol 3 (2022)
Background The Veterans Health Administration (VHA) developed the Stratification Tool for Opioid Risk Mitigation (STORM) dashboard to assist in identifying Veterans at risk for adverse opioid overdose or suicide-related events. In 2018, a policy was
Externí odkaz:
https://doaj.org/article/332f93d9ac6b4e4eac68047cab0045d2
Autor:
Rahul Aggarwal, Joshi J. Alumkal, Russell Z. Szmulewitz, Celestia S. Higano, Alan H. Bryce, Angela Lopez-Gitlitz, Sharon A. McCarthy, Branko Miladinovic, Kelly McQuarrie, Shibu Thomas, Ke Zhang, Eric J. Small
Publikováno v:
Prostate Cancer, Vol 2022 (2022)
Purpose. This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC). Materials and Methods. Patients
Externí odkaz:
https://doaj.org/article/ca0c2ba8c68e4aca981effd45231b1a2
Autor:
Shari S. Rogal, Matthew Chinman, Walid F. Gellad, Maria K. Mor, Hongwei Zhang, Sharon A. McCarthy, Genna T. Mauro, Jennifer A. Hale, Eleanor T. Lewis, Elizabeth M. Oliva, Jodie A. Trafton, Vera Yakovchenko, Adam J. Gordon, Leslie R. M. Hausmann
Publikováno v:
Implementation Science, Vol 15, Iss 1, Pp 1-11 (2020)
Abstract Background In 2018, the Department of Veterans Affairs (VA) issued Notice 2018-08 requiring facilities to complete “case reviews” for Veterans identified in the Stratification Tool for Opioid Risk Mitigation (STORM) dashboard as high ris
Externí odkaz:
https://doaj.org/article/0382b6e286a4454fadd5fc3ce3342588
Autor:
Shibu Thomas, Fabio Franke, Sabine Brookman-May, Thomas Steuber, Daphne Wu, Susan Li, Fred Saad, Hiroyoshi Suzuki, Sharon Anne McCarthy, Katherine B. Bevans, Peter De Porre, Thomas W. Flaig, Eleni Efstathiou, Jinhui Li, Suneel Mundle, Oscar B. Goodman, Gerhardt Attard, Stéphane Oudard, Kesav Yeruva, Dana E. Rathkopf
Publikováno v:
The Lancet Oncology. 22:1541-1559
Summary Background The majority of patients with metastatic castration-resistant prostate cancer (mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by both activated androgen receptors and elevated intratumoural andro
Autor:
Dingwei Ye, Katherine B. Bevans, Andrea J. Pereira de Santana Gomes, Sabine Brookman-May, Byung Ha Chung, Simon Chowdhury, Suneel Mundle, Álvaro Juárez, Ke Zhang, Kim N. Chi, Mustafa Ozguroglu, Anders Bjartell, Sharon Anne McCarthy, Julie S. Larsen, Neeraj Agarwal, Weili Sun, Robert Given, Nibedita Bandyopadhyay, Hirotsugu Uemura, Axel S. Merseburger
Publikováno v:
Journal of Clinical Oncology. 39:2294-2303
PURPOSE The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sen
Autor:
Fred Saad, Peter De Porre, Sabine Brookman-May, Jinhui Li, Sharon A McCarthy, Dana E Rathkopf
Publikováno v:
The Lancet. Oncology. 23(1)
Autor:
Anders Bjartell, Kim N. Chi, Lawrence Karsh, Sabine Brookman-May, Clemente Aguilar-Bonavides, Álvaro Juárez Soto, Shibu Thomas, Simon Chowdhury, Robert Given, Andrea J. Pereira de Santana Gomes, Florence Lefresne, Sharon Anne McCarthy, Suneel Mundle, Neeraj Agarwal, Axel S. Merseburger, Hirotsugu Uemura, Amitabha Bhaumik, Justin Lucas
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The final analysis of TITAN confirmed improvement in long-term outcomes in metastatic castration-sensitive prostate cancer (mCSPC) with apalutamide (APA) + androgen depri...
Autor:
Eric J. Small, Fred Saad, Julie S. Larsen, Neeraj Agarwal, Suneel Mundle, Simon Chowdhury, Matthew R. Smith, Julie N. Graff, Stéphane Oudard, Gang Li, Angela Lopez-Gitlitz, Kim N. Chi, Sharon Anne McCarthy
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The phase 3 TITAN and SPARTAN studies demonstrated improved outcomes with the addition of apalutamide (APA) to androgen deprivation therapy (ADT); outcomes included prolo...
Autor:
Yusoke Koroki, SuYeon Jeong, Jian Huang, Zhang-Qun Ye, Byung Ha Chung, Suneel Mundle, Sharon Anne McCarthy, Dalin He, Dingwei Ye, Kim N. Chi, Choung Soo Kim, Gaku Arai, Yuan-Yuan Zhang, Hirotsugu Uemura, Spyros Triantos
Publikováno v:
Asian journal of andrology. 24(2)
Ethnicity might be associated with treatment outcomes in advanced prostate cancer. This study aimed to evaluate the efficacy and safety of androgen deprivation therapy (ADT) combined with apalutamide in East Asians with metastatic castration-sensitiv
Autor:
Sant P. Chawla, Shreyaskumar Patel, Martee L. Hensley, George Wang, Roland Elmar Knoblauch, Arun S. Singh, Trilok V. Parekh, Daniel A. Rushing, Christopher W. Ryan, Robert G. Maki, Gina Z. D'Amato, Charles Forscher, Pamela E. Kaiser, Michael B. Livingston, Sharon Anne McCarthy, Damon R. Reed, George D. Demetri, John A. Charlson, Rahul Seth, Margaret von Mehren
Publikováno v:
Cancer
Background We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously‐treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). Methods Patients were randomized 2:1 to trabectedin (n = 384) or dacarbazine (n = 193) ad